You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Medtronic
Colorcon
Merck
Mallinckrodt

Last Updated: April 6, 2020

DrugPatentWatch Database Preview

Claims for Patent: 6,830,923

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,830,923
Title: Genetics units for inhibiting the function of RNA
Abstract:The invention relates to a genetic unit, optionally present as a multiple-copy, for inhibiting RNA. The unit contains the transcription units necessary for transcription by polymerase III and a DNA coding for inhibiting RNA, which is arranged within the unit in such a way that the transcribed RNA is part of the polymerase III transcript. Using these units it is possible to achieve increased stability of the inhibiting RNA, which may occur in the form of ribozymes or antisense-RNAs, whilst maintaining an undiminished activity. The invention further relates to a process for introducing the genetic units into the cell, the use of these units and pharmaceutical preparations containing them.
Inventor(s): Beug; Hartmut (Vienna, AT), Birnstiel; Max L. (Vienna, AT), Cotten; Matthew (Vienna, AT), Wagner; Ernst (Langenzersdorf, AT), Kandolf; Harald (Vienna, AT)
Assignee: Boehringer Inglheim International GmbH (Ingelheim am Rhein, DE)
Application Number:07/947,982
Patent Claims:1. A polynucleotide molecule, comprising: (a) a first polynucleotide molecule coding for a tRNA; and (b) a second polynucleotide molecule coding for a ribozyme, said second polynucleotide molecule being located between the A- and B-boxes of said first polynucleotide molecule.

2. The polynucleotide molecule of claim 1, wherein said first polynucleotide molecule comprises an ApaI restriction site located between said A and B boxes, and said second polynucleotide molecule is inserted in said ApaI restriction site.

3. The polynucleotide molecule of claim 1, wherein said ribozyme is a hammerhead-type ribozyme.

4. The polynucleotide molecule of claim 1, wherein said first polynucleotide molecule codes for initiation-met tRNA.

5. The polynucleotide molecule of claim 1, wherein said first polynucleotide molecule codes for tyr-tRNA.

6. The polynucleotide molecule of claim 1, further comprising an intron, wherein said intron is part of said second polynucleotide molecule.

7. The polynucleotide molecule of claim 6, wherein said intron is modified by first insertion of a restriction site and a second insertion of nucleotides complimentary to the anticodon triplet, so that the secondary structure of the precursor tRNA is stabilized, while the structures which are critical for splicing are maintained.

8. The polynucleotide molecule of claim 1, wherein said first polynucleotide molecule codes for a tRNA having an anticodon stem and loop region, and wherein said anticodon stem and loop region is longer than the anticodon stem and loop region of the wild-type tRNA.

9. The polynucleotide molecule of claim 8, further comprising a restriction site introduced into the anticodon stem and loop region, and wherein said second polynucleotide molecule is inserted in said restriction site.

10. A polynucleotide molecule, comprising: (a) a first polynucleotide molecule coding for a tRNA; (b) a second polynucleotide molecule coding for a ribozyme, said second polynucleotide molecule being located between the A- and B-boxes of said first polynucleotide molecule; and (c) an intron that is part of said second polynucleotide molecule.

11. The polynucleotide molecule of claim 10, wherein said intron is modified by a first insertion of a restriction site and a second insertion of nucleotide complimentary to the anticodon triplet, so that the secondary structure of the precursor tRNA is stabilized, while the structures which are critical for splicing are maintained.

12. A polynucleotide molecule, comprising: (a) a first polynucleotide molecule coding for a tRNA having an anticodon stem and loop region, wherein said anticodon stem and loop region is longer than the anticodon stem and loop region of the wild-type tRNA; and (b) a second polynucleotide molecule coding for a ribozyme, said second polynucleotide molecule being located between the A- and B-boxes of said first polynucleotide molecule.

13. A polynucleotide molecule, comprising: (a) a first polynucleotide molecule that is transcribed by RNA polymerase III; and (b) a second polynucleotide molecule coding for an RNA-inhibiting RNA located within said first polynucleotide molecule, wherein said RNA-inhibiting RNA is not an antisense molecule.

14. The polynucleotide molecule of claim 13, wherein said first polynucleotide molecule codes for a tRNA.

15. The polynucleotide molecule of claim 14, wherein said first polynucleotide molecule codes for initiation-met tRNA.

16. The polynucleotide molecule of claim 14, wherein said first polynucleotide molecule codes for tyr-tRNA.

17. The polynucleotide molecule of claim 14, further comprising an intron, wherein said intron is part of said second polynucleotide molecule.

18. The polynucleotide molecule of claim 14, wherein said first polynucleotide molecule codes for a tRNA having an anticodon stem and loop region, and wherein said anticodon stem and loop region is longer than the anticodon stem and loop region of the wild-type tRNA.

19. The polynucleotide molecule of claim 18, further comprising a restriction site introduced into the anticodon stem and loop region, and wherein said second polynucleotide molecule is inserted in said restriction site.

20. A nucleic acid molecule, comprising: (a) a first polynucleotide molecule that is transcribed by RNA polymerase III; and (b) a second polynucleotide molecule coding for an RNA-inhibiting RNA that is not an antisense molecule, wherein said second polynucleotide molecule is inserted within said first polynucleotide molecule in such a way that, when said nucleic acid molecule is transcribed by RNA polymerase III, the transcription rate of said nucleic acid molecule and the stability of the resulting transcript are maintained.

21. The nucleic acid molecule of claim 20, wherein said RNA-inhibiting RNA is a ribozyme.

22. The nucleic acid molecule of claim 20, wherein said first polynucleotide molecule codes for a tRNA.

23. The nucleic acid molecule of claim 20, wherein said first polynucleotide molecule codes for initiation-met tRNA.

24. The nucleic acid molecule of claim 20, wherein said first polynucleotide molecule codes for tyr-tRNA.

25. The nucleic acid molecule of claim 20, further comprising an intron, wherein said intron is part of said second polynucleotide molecule.

26. The nucleic acid molecule of claim 20, wherein said first polynucleotide molecule codes for a tRNA having an anticodon stem and loop region, and wherein said anticodon stem and loop region is longer than the anticodon stem and loop region of the wild-type tRNA.

27. The nucleic acid molecule of claim 26, further comprising a restriction site introduced into the anticodon stem and loop region, and wherein said second polynucleotide molecule is inserted in said restriction site.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
AustriaA 609/89Mar 16, 1989

Details for Patent 6,830,923

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Boehringer Inglheim International GmbH (Ingelheim am Rhein, DE) 2021-12-14 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Boehringer Inglheim International GmbH (Ingelheim am Rhein, DE) 2021-12-14 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Boehringer Inglheim International GmbH (Ingelheim am Rhein, DE) 2021-12-14 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Johnson and Johnson
McKesson
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.